Figure 11. Semilogarithmic plots of the concentrations of buprenorphine (1) in
plasma divided by the dose in mg/kg (cone./dose) plotted against time (min) for
the 1.6369 mg/kg (Study #2, O )> 2.5632 mg/kg (Study #3, ), and 4.69 mg/kg
(Study #7, on the presumption of IV bolus administration) doses of
buprenorphine in dog B. The middle inset is the plot of the data for the first 200
min after administration, and the top inset is the continuation of the data on an
extended time scale. The data for the highest dose, 4.69 mg/kg (Study #7, (\>) was
derived from the IV infusion study in which buprenorphine was infused at the rate
of 0.5058 mg/min for 165 min. The superimposition of the infusion data on the IV
bolus data was effected by the procedure described in this chapter under the
subheading "Dose-independent pharmacokinetics of buprenorphine". The points ((\,)
for the infusion study were calculated on the premise of IV bolus administration
of 4.69 mg/kg dose of buprenorphine in accordance with the equation 2. The
parameters of equation 2 were obtained through equations 15-18. The nonparametric
rank sum test (Kruskal-Wallis test, Appendix III; see also reference 59) was used
to test the hypothesis (H') that the dose-normalised plasma concentrations at the
above three dose levels were drawn from identical distributions. The critical
value of chi-square with a =0.05 and df=2 is 5.99. The observed H' (-7) is less
than 5.99. Therefore it can be concluded that there is no difference among the
three groups.